Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 8/20 | 0.32 |
| ▸ | CNR2 | P34972 | 8/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | RARB | P10826 | 2/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20322738 | 1.00 | RAB9A (0.33) | RAB9AP2RY14CNR1CNR2CYP2C9 | |
| SCHEMBL19854219 | 0.93 | RAB9A (0.37) | RAB9AP2RY14CNR1CNR2CYP2C9 | |
| SCHEMBL19855316 | 0.93 | RAB9A (0.37) | RAB9AP2RY14CNR1CNR2CYP2C9 | |
| SCHEMBL19854416 | 0.93 | RAB9A (0.37) | RAB9AP2RY14CNR1CNR2CYP2C9 | |
| SCHEMBL20322699 | 0.93 | MMP2 (0.36) | PPARGPPARA | |
| SCHEMBL20322680 | 0.93 | FFAR4 (0.32) | RAB9A | |
| SCHEMBL20322630 | 0.91 | CYP2C9 (0.36) | CYP2C9PPARGPPARAALDH1A1LMNA | |
| SCHEMBL20322718 | 0.90 | ITGB3 (0.34) | CNR1CNR2CYP2C9RARBS1PR3 | |
| SCHEMBL20407450 | 0.89 | ALDH1A1 (0.35) | RAB9AP2RY14CNR1CNR2CYP2C9 | |
| SCHEMBL20322608 | 0.89 | PPARG (0.32) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | C1S, CCND1, C5 | RAB9A 3952/4885P2RY14 3341/4885CNR1 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.